title: Mycophenolate mofetil monotherapy in liver transplantation.
abstract: Chronic renal failure is a major cause of morbidity and mortality after orthotopic liver transplantation. We did a randomised controlled trial of mycophenolate mofetil monotherapy in liver transplant patients who developed renal failure associated with calcineurin-inhibitor (ciclosporin or tacrolimus) immunosuppressive therapy. Although renal failure improved when the calcineurin-inhibitor dose was reduced and ultimately stopped, the trial was stopped when three of five patients on monotherapy developed organ rejection requiring a second transplantation.
authors.forename: S F
authors.initials: SF
authors.lastname: Stewart
authors.forename: M
authors.initials: M
authors.lastname: Hudson
authors.forename: D
authors.initials: D
authors.lastname: Talbot
authors.forename: D
authors.initials: D
authors.lastname: Manas
authors.forename: C P
authors.initials: CP
authors.lastname: Day
mesh_terms: D065095:Calcineurin Inhibitors; D002908:Chronic Disease; D016572:Cyclosporine / Q000009:adverse effects*; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D007168:IMP Dehydrogenase / Q000037:antagonists & inhibitors*; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D016031:Liver Transplantation; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use*; D051437:Renal Insufficiency / Q000139:chemically induced*; D016559:Tacrolimus / Q000009:adverse effects*
chemical_list: D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D007168:IMP Dehydrogenase; D009173:Mycophenolic Acid; D016559:Tacrolimus